07:00 , Apr 9, 2012 |  BC Week In Review  |  Company News

Swedish Orphan Biovitrum deal

Swedish Orphan agreed to settle the remaining development and milestone obligations owed to the former stockholders of Arexis AB , which Swedish Orphan acquired in 2005. Swedish Orphan will pay to the former stockholders SEK77...
07:00 , May 10, 2010 |  BC Week In Review  |  Company News

Swedish Orphan Biovitrum deal

Swedish Orphan Biovitrum will make a milestone payment of SEK12.4 million ($1.7 million) through the issuance of 282,425 shares to the former stockholders of Arexis AB . The payment, created under the terms of the...
07:00 , Sep 22, 2008 |  BioCentury  |  Strategy

Global reinvention

Biovitrum AB has reinvented itself twice since it was formed in 2001. Last week's deal with Amgen Inc. is directly in line with its latest incarnation as a specialty care-focused biotech that is looking to...
08:00 , Jan 22, 2007 |  BC Week In Review  |  Company News

Biovitrum metabolic, inflammation news

BVT will close its Gothenburg site and transfer all research and projects to its Stockholm site. BVT acquired the Gothenburg site when it bought Arexis AB in 2005 (see BioCentury, Aug. 29, 2005). All 19...
07:00 , Oct 10, 2005 |  BC Week In Review  |  Company News

Biovitrum metabolic, endocrine, inflammation news

Biovitrum will restructure its research to focus on later stage discovery programs and clinical development and, as a result, may reduce its headcount by 70-100 from about 580 employees. The move follows the company's recent...
01:16 , Oct 7, 2005 |  BC Extra  |  Company News

Biovitrum restructures research

Biovitrum (Stockholm, Sweden) said it will restructure its research to focus on later stage discovery programs and clinical development and, as a result, may reduce its headcount by 70-100 from about 580 employees. The move...
07:00 , Aug 29, 2005 |  BC Week In Review  |  Company News

Arexis, Biovitrum deal

Biovitrum acquired metabolic and inflammatory disease company Arexis for an undisclosed amount of cash and stock. Biovitrum develops compounds for obesity, diabetes and inflammation, and also is focused on oncology and glaucoma. Arexis' recombinant bile...
07:00 , Aug 29, 2005 |  BioCentury  |  Strategy

Biovitrum checks the boxes

Biovitrum AB went from being a Phase II company to a preclinical company after its two lead products failed in 2003 and 2004. Since then, the Swedish company has replenished its pipeline, acquiring several clinical...
07:00 , Aug 29, 2005 |  BioCentury  |  Strategy

Biovitrum's pipeline

Biovitrum's pipeline Biovitrum's pipeline After lead compounds BVT.933 and BVT.3498 (AMG 331) failed in the clinic in 2003 and 2004, Biovitrum set out to fill its pipeline via acquisitions, and early this year set itself...
00:22 , Aug 23, 2005 |  BC Extra  |  Company News

Biovitrum acquires Arexis

Biovitrum (Stockholm, Sweden) acquired metabolic and inflammatory disease company Arexis (Gothenburg, Sweden) for an undisclosed amount of cash and stock. Biovitrum develops compounds for obesity, diabetes and inflammation, and also is focused on oncology and...